Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smoking cessation study

This article was originally published in The Tan Sheet

Executive Summary

Nicotine replacement therapy with OTC gum or patch "at least" as good as Rx treatment, study conducted by Saul Shiffman, MD, University of Pittsburgh, et al., concludes. Published in May issue of Addiction, research involved contrasting data from parallel, independent studies assessing usage, outcomes from GlaxoSmithKline's Nicorette gum and NicoDerm CQ patch in simulated OTC and "real world" Rx settings. Abstinence after six weeks and six months of treatment was compared. The OTC evaluation enrolled 5,348 smokers, while Rx use information was obtained from 933 smokers who had filed prescriptions for treatments...

You may also be interested in...



NRT Outcomes In California Study Counter “Authoritative” Data – GSK

Recently published data indicating nicotine replacement therapy efficacy has diminished over the years with OTC availability is at odds with "authoritative reviews and conclusions" supporting the use of such products, GlaxoSmithKline maintained

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Topics

UsernamePublicRestriction

Register

PS093978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel